Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers-Reference-Cited by-同舟云学术

Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers

Published:2016-05-23 Issue:7607 Volume:534 Page:402-406
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Kataoka Keisuke,Shiraishi Yuichi,Takeda Yohei,Sakata Seiji,Matsumoto Misako,Nagano Seiji,Maeda Takuya,Nagata Yasunobu,Kitanaka Akira,Mizuno Seiya,Tanaka Hiroko,Chiba Kenichi,Ito Satoshi,Watatani Yosaku,Kakiuchi Nobuyuki,Suzuki Hiromichi,Yoshizato Tetsuichi,Yoshida Kenichi,Sanada Masashi,Itonaga Hidehiro,Imaizumi Yoshitaka,Totoki Yasushi,Munakata Wataru,Nakamura Hiromi,Hama Natsuko,Shide Kotaro,Kubuki Yoko,Hidaka Tomonori,Kameda Takuro,Masuda Kyoko,Minato Nagahiro,Kashiwase Koichi,Izutsu Koji,Takaori-Kondo Akifumi,Miyazaki Yasushi,Takahashi Satoru,Shibata Tatsuhiro,Kawamoto Hiroshi,Akatsuka Yoshiki,Shimoda Kazuya,Takeuchi Kengo,Seya Tsukasa,Miyano Satoru,Ogawa Seishi

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/nature18294.pdf

Reference40 articles.

1. Iwai, Y. et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl Acad. Sci. USA 99, 12293–12297 (2002)

2. Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443–2454 (2012)

3. Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455–2465 (2012)

4. Topalian, S. L., Drake, C. G. & Pardoll, D. M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27, 450–461 (2015)

5. Page, D. B., Postow, M. A., Callahan, M. K., Allison, J. P. & Wolchok, J. D. Immune modulation in cancer with antibodies. Annu. Rev. Med. 65, 185–202 (2014)

Cited by 534 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of PD‐1 in Skin Cancer: Molecular Mechanism, Clinical Applications, and Resistance;Chemical Biology & Drug Design;2024-09

2. The Genetic Analysis and Clinical Therapy in Lung Cancer: Current Advances and Future Directions;Cancers;2024-08-19

3. Immune modulatory microRNAs in tumors, their clinical relevance in diagnosis and therapy;Journal for ImmunoTherapy of Cancer;2024-08

4. Advances and prospects of biomarkers for immune checkpoint inhibitors;Cell Reports Medicine;2024-07

5. PD-L1 at the crossroad between RNA metabolism and immunosuppression;Trends in Molecular Medicine;2024-07